AIP
BIO icon

Arrowpoint Investment Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Arrowpoint Investment Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,888
Closed -$572K – 100
2025
Q4 		$572K Buy
+1,888
New +$589K 0.08% 68

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Arrowpoint Investment Partners's BIO Position: Q1 2026 in Review

Arrowpoint Investment Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 1,888 shares — an estimated $572K sold.

Arrowpoint Investment Partners first reported a position in BIO in Q4 2025 and held it in 1 quarter. The position peaked at $572K in Q4 2025. 395 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Arrowpoint Investment Partners reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
  • Arrowpoint Investment Partners sold 1,888 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $572K.
  • Arrowpoint Investment Partners first reported a position in Bio-Rad Laboratories Class A in Q4 2025 and held it in 1 quarter.
  • Arrowpoint Investment Partners's Bio-Rad Laboratories Class A position peaked at $572K in Q4 2025.
  • 395 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.